Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT06790602 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (mPDAC)

Interventions

DRUG: Cemiplimab Plus Gemcitabine

Sponsor

University of California, San Diego

Collaborators

[object Object]